These results elucidate a mechanism which we believe to be novel underlying corticotroph tumorigenesis, and it also provide a rationale for CIRP as a potential therapeutic target to abrogate corticotroph tumor growth and/or ACTH hypersecretion. This evidence concerns the gene POMC and neoplasm.